Zobrazeno 1 - 8
of 8
pro vyhledávání: '"TIANJIA MA"'
Publikováno v:
BMC Urology, Vol 18, Iss 1, Pp 1-3 (2018)
Abstract Background Uretero-fallopian fistula (UFF) is a very rare surgery complication which usually happens after surgeries of fallopian tube or ureter. There has been no report of interventional operations of fallopian tube causing UFF. Case prese
Externí odkaz:
https://doaj.org/article/c17ae09fd61f41fcb1575ccc979719ce
Autor:
PAN XIAO1, TIANJIA MA1, CHUNWEN ZHOU1, YANG XU1, YUQIANG LIU1, HUAIQIANG ZHANG1 huaiqiangzhang@yeah.net
Publikováno v:
Molecular Medicine Reports. 2016, Vol. 13 Issue 5, p4079-4084. 6p.
Autor:
Tianjia, Ma, Wenzhen, Wang, Zhaoqun, Jiang, Guangfeng, Shao, Liqiang, Guo, Junjia, Li, Lei, Zhang, Yuqiang, Liu
Publikováno v:
Zhonghua yi xue za zhi. 95(37)
To compare the differential effects of narrow band imaging (NBI)-assisted holmium laser with transurethral resection on the 1-year recurrence rate of non-muscle invasive bladder cancer (NMIBC), and to evaluate the clinical values of NBI-assisted holm
Publikováno v:
Molecular medicine reports. 13(5)
Prostate cancer is a common multiple malignant tumor occurring in males. Prostate cancer mortality is the 2nd most common of all tumor types in Western countries and the mortality of morbidity is 13% in the USA. The present study aimed to investigate
Publikováno v:
Zhonghua yi xue za zhi. 94(38)
To explore the expressions of cancerous inhibitor of protein phosphatase 2A (CIP2A) and osteopontin (OPN) and evaluate their roles in bladder cancer.RNA was isolated from 38 cases of patients with bladder cancer and 12 cases of normal bladder tissue
Publikováno v:
Zhonghua yi xue za zhi. 94(34)
To explore the expression of cancerous inhibitor of PP2A (CIP2A) and evaluate its role in bladder cancer.RT-PCR was used to detect the expression of CIP2A mRNA from 38 cases of patients with bladder cancer and 12 cases of normal bladder tissue. The C
Publikováno v:
Bioscience Reports; 12/21/2018, Vol. 38 Issue 6, p1-9, 9p, 5 Graphs
Publikováno v:
Urologia internationalis. 95(1)
Objectives: Docetaxel was the first drug with proven survival benefit in men with castration-resistant prostate cancer. Acquired resistance to docetaxel precedes fatality in castration-resistant prostate cancer. The aims of this study were to evaluat